CG Oncology director sells exercised shares
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share.
Rhea-AI Filing Summary
CG Oncology, Inc. director James Mulay exercised a fully vested director stock option to acquire 24,165 shares of common stock at an exercise price of $26.63 per share. He then sold 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 27, 2026, with individual sale prices ranging from $74.98 to $75.79. After these transactions, this report shows 0 common shares and 0 related director stock options remaining in the reported accounts.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 24,165 shares ($1.17M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Mulay James
Role
Director
Sold
24,165 shs ($1.82M)
Approx. gross sale proceeds
$1.82M
Approx. exercise cost
$644K
Approx. pre-tax spread
$1.17M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Director Stock Option (right to buy) F3 | 24,165 | $0.00 | $0.00 |
| Exercise | Common Stock | 24,165 | $26.63 | $644K |
| Sale | Common Stock F1, F2 | 24,165 | $75.16 | $1.82M |
Holdings After Transaction:
Director Stock Option (right to buy) — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
- F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.98 to $75.79 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3. Fully vested.
Key Figures
Shares sold: 24,165 shares
Weighted average sale price: $75.16 per share
Sale price range: $74.98–$75.79 per share
+5 more
8 metrics
Shares sold
24,165 shares
Common stock sold in open-market transaction on 2026-07-10
Weighted average sale price
$75.16 per share
Average price for 24,165 shares sold on 2026-07-10
Sale price range
$74.98–$75.79 per share
Range of prices for multiple sale transactions on 2026-07-10
Option exercise shares
24,165 shares
Shares acquired by exercising Director Stock Option on 2026-07-10
Option exercise price
$26.63 per share
Exercise price for Director Stock Option (right to buy)
Rule 10b5-1 plan adoption date
March 27, 2026
Date James Mulay adopted the trading plan governing these sales
Option expiration date
June 4, 2035
Original expiration date of the exercised Director Stock Option
Net shares sold
24,165 shares
Net buy/sell shares from transaction summary (net-sell direction)
Key Terms
Rule 10b5-1 trading plan, weighted average price, Director Stock Option (right to buy), derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
Director Stock Option (right to buy) financial
"security_title": "Director Stock Option (right to buy)""
derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
FAQ
What insider transaction did CG Oncology (CGON) director James Mulay report?
Director James Mulay reported exercising a fully vested director stock option for 24,165 CG Oncology common shares at $26.63 per share, then selling the same 24,165 shares in an open-market transaction at a weighted average price of $75.16 per share.
What stock option did James Mulay exercise in this CGON filing?
Mulay exercised a fully vested Director Stock Option (right to buy) covering 24,165 shares of CG Oncology common stock at an exercise price of $26.63 per share. The option, which previously had an expiration date of June 4, 2035, is shown as fully exercised.
AI-generated analysis. How Rhea-AI works. Not financial advice.
